DELFT, The Netherlands, June 25,
2024 /PRNewswire/ -- InnoGI Technologies, a
pioneer and leader in innovative gastrointestinal research, proudly
announces the appointment of Dr. Hajime
Endo as its Strategic Commercial Advisor.
With a distinguished career spanning more than three decades, Dr.
Endo brings a wealth of experience and expertise to the
company.
Dr. Endo's leadership as both Chairman and President of Lonza
Japan exemplifies his ability to drive organizational success and
innovation. His extensive experience at renowned organizations such
as Lonza, Hoechst, and Procter & Gamble positions
him as a seasoned leader and role model in the field.
In addition to his corporate accomplishments, Dr. Endo's
involvement as a Board Member at the Japanese Institute for Health
Food Standards (JIHFS) highlights his
commitment to improving health standards in Japan, reflecting his dedication to societal
development and wellbeing.
"We are thrilled to welcome Dr. Hajime Endo to the InnoGI Technologies team as
our Strategic Commercial Advisor," says Dr. Behzad
Mahdavi,PhD, MBA, CEO of InnoGI Technologies.
"His profound expertise and proven track record in commercial
strategy and business development will be invaluable as we continue
to revolutionize the field of gastrointestinal research with
disruptive technologies."
Expressing his excitement about joining InnoGI Technologies, Dr.
Endo remarked, "I am thrilled to be a part of InnoGI
Technologies, an organization at the forefront of innovation with
its state-of-the-art SurroGUT™ Platform. It has high potential
to replace animal testing with more accurate predictions of oral
drug behavior in the human GI tract, shortening the time-to-market
for our customers. I am very much interested in seeing fewer
animals used for testing in the future."
Dr. Endo has a Ph.D. in Chemistry from Rice
University, Houston, Texas,
USA, and has been recognized for his scientific achievements with
prestigious fellowships such as the Alexander von Humboldt
Fellowship at the Institute of Physical Chemistry, University of
Göttingen, Germany.
In his new role, Dr. Endo will provide strategic guidance and
leadership to InnoGI Technologies, leveraging his profound
experience to drive commercial success and propel the company's
SurroGUT™ platform, which accurately mimics the human GI tract, to
new heights.
About SurroGUT™ and InnoGI Technologies
InnoGI
Technologies, formerly The TIM Company, headquartered in Delft,
Netherlands, is an innovative CRO
and technology provider for the pharmaceutical and food industries.
Its SurroGUT™ platform uses advanced in vitro models such as
TIM, mimicking with high fidelity the human gut. TIM replicates
dynamically changing GI pH profiles, peristalsis and enzyme and
digestive fluid secretions at true to life rates. The TIM
Technology has been used to evaluate more than 250 active
pharmaceutical ingredients in commercial drug products and guided
clients worldwide with decision-making at different stages of oral
drug development. This reduces the number of formulation
iterations, de-risks clinical trials, and shortens the
time-to-market, as evidenced in more than 260 scientific
publications. For more information, visit our website
(www.innogitechnologies.com or
www.thetimcompany.com) or follow us
on LinkedIn.
Media Contact:
Nouschka Verboon
0611256065
379564@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/innogi-technologies-announces-the-appointment-of-dr-hajime-endo-former-chairman-and-president-of-lonza-japan-and-jihfs-board-member-as-strategic-commercial-advisor-302181218.html
SOURCE InnoGI Technologies